{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:16:17Z","timestamp":1795094177764,"version":"4.10.2"},"reference-count":190,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>While Alzheimer\u2019s dementia (AD) has a prevalence as high as 3-32% and is associated\nwith cognitive dysfunction and the risk of institutionalization, no efficacious and acceptable treatments can modify\nthe course of cognitive decline in AD. Potential benefits of exogenous melatonin for cognition have been divergent\nacross trials.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The current network meta-analysis (NMA) was conducted under the frequentist model to evaluate the\npotential beneficial effects of exogenous melatonin supplementation on overall cognitive function in participants\nwith AD in comparison to other FDA-approved medications (donepezil, galantamine, rivastigmine, memantine,\nand Namzaric).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The primary outcome was the changes in the cognitive function [measured by mini-mental state examination\n(MMSE)] after treatment in patients with Alzheimer\u2019s dementia. The secondary outcomes were changes\nin the quality of life, behavioral disturbance, and acceptability (i.e., drop-out due to any reason and rate of any\nadverse event reported).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The current NMA of 50 randomized placebo-controlled trials (RCTs) revealed the medium-term lowdose\nmelatonin to be associated with the highest post-treatment MMSE (mean difference = 1.48 in MMSE score,\n95% confidence intervals [95% CIs] = 0.51 to 2.46) and quality of life (standardized mean difference = -0.64,\n95% CIs = -1.13 to -0.15) among all of the investigated medications in the participants with AD. Finally, all of\nthe investigated exogenous melatonin supplements were associated with similar acceptability as was the placebo.\nConclusion: The current NMA provides evidence for the potential benefits of exogenous melatonin supplementation,\nespecially medium-term low-dose melatonin, in participants with AD.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p>The current NMA provides evidence for the potential benefits of exogenous melatonin supplementation,\nespecially medium-term low-dose melatonin, in participants with AD.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Trial Registration:<\/jats:title>\n<jats:p>The current study complies with the Institutional Review Board of the Tri-Service General\nHospital (TSGHIRB: B-109-29) and had been registered in PROSPERO (CRD42020193088).<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x20666220420122322","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T07:20:56Z","timestamp":1650612056000},"page":"1816-1833","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Dose and Duration-dependent Association between Melatonin Treatment\nand Overall Cognition in Alzheimer\u2019s Dementia: A Network Meta-\nAnalysis of Randomized Placebo-Controlled Trials"],"prefix":"10.2174","volume":"20","author":[{"given":"Yow-Ling","family":"Shiue","sequence":"first","affiliation":[{"name":"Institute of Biomedical Sciences, National Sun Yat-Sen\nUniversity, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Tao","family":"Tseng","sequence":"additional","affiliation":[{"name":"Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung, Taiwan"},{"name":"Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan"},{"name":"Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan"},{"name":"Clinical Psychology Center, Asia University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Yan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, E-DA Dachang\nHospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Pai","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kuang Tien General Hospital, Taichung, Taiwan"},{"name":"Department of Nutrition,\nHuangkuang University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Pin","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Psychiatry & Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan"},{"name":"College of Medicine, China Medical University, Taichung, Taiwan"},{"name":"An-Nan Hospital, China Medical University, Tainan, Taiwan"},{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Tri-Service General Hospital; School of Medicine,\nNational Defense Medical Center, Taipei, Taiwan"},{"name":"Institute of Brain Science, National Yang Ming Chiao Tung University, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Cheng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Landseed International Hospital, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kang","family":"Tu","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology & Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Dentistry, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pao-Yen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan"},{"name":"Institute for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre F.","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Stubbs","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"},{"name":"Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London, UK"},{"name":"Faculty of Health, Social Care Medicine and Education, Anglia Ruskin University, Chelmsford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka J.","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Psychiatry & Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan"},{"name":"Former Division Chief of Health Care Research, National Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian-Jeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Addiction Science, Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Sung","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Beitou Branch, Tri-Service General Hospital; School of Medicine, National Defense Medical Center, Taipei, Taiwan"},{"name":"Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk-Kwan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, E-Da Hospital, I-Shou University School of Medicine for International Students, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shian","family":"Cheng","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan"},{"name":"Department of Psychiatry, Tsyr-Huey Mental Hospital,\nKaohsiung Jen-Ai\u2019s Home, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Yang","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan"},{"name":"Clinical Psychology Center, Asia University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","volume":"80","author":"Hebert L.E.","year":"2013","unstructured":"Hebert L.E.; Weuve J.; Scherr P.A.; Evans D.A.; Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013,80(19),1778-1783","journal-title":"Neurology"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/(SICI)1099-1166(200002)15:2<181::AID-GPS96>3.0.CO;2-I","volume":"15","author":"Gonz\u00e1lez-Salvador T.","year":"2000","unstructured":"Gonz\u00e1lez-Salvador T.; Lyketsos C.G.; Baker A.; Hovanec L.; Roques C.; Brandt J.; Steele C.; Quality of life in dementia patients in long-term care. Int J Geriatr Psychiatry 2000,15(2),181-189","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1001\/jama.299.22.2642","volume":"299","author":"Riemersma-van der Lek R.F.","year":"2008","unstructured":"Riemersma-van der Lek R.F.; Swaab D.F.; Twisk J.; Hol E.M.; Hoogendijk W.J.; Van Someren E.J.; Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: A randomized controlled trial. JAMA 2008,299(22),2642-2655","journal-title":"JAMA"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/(SICI)1099-1166(199804)13:4<248::AID-GPS770>3.0.CO;2-0","volume":"13","author":"Donaldson C.","year":"1998","unstructured":"Donaldson C.; Tarrier N.; Burns A.; Determinants of carer stress in Alzheimer\u2019s disease. Int J Geriatr Psychiatry 1998,13(4),248-256","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/archpsyc.1997.01830150083012","volume":"54","author":"Devanand D.P.","year":"1997","unstructured":"Devanand D.P.; Jacobs D.M.; Tang M.X.; Del Castillo-Castaneda C.; Sano M.; Marder K.; Bell K.; Bylsma F.W.; Brandt J.; Albert M.; Stern Y.; The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997,54(3),257-263","journal-title":"Arch Gen Psychiatry"},{"key":"ref=6","first-page":"433","volume":"60","author":"Moore A.","year":"2014","unstructured":"Moore A.; Patterson C.; Lee L.; Vedel I.; Bergman H.; Fourth Canadian consensus conference on the diagnosis and treatment of dementia: Recommendations for family physicians. Can Fam Physician 2014,60(5),433-438","journal-title":"Can Fam Physician"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1111\/bph.14197","volume":"175","author":"Vald\u00e9s-Tovar M.","year":"2018","unstructured":"Vald\u00e9s-Tovar M.; Estrada-Reyes R.; Sol\u00eds-Chagoy\u00e1n H.; Argueta J.; Dorantes-Barr\u00f3n A.M.; Quero-Ch\u00e1vez D.; Cruz-Gardu\u00f1o R.; Cerc\u00f3s M.G.; Trueta C.; Oikawa-Sala J.; Dubocovich M.L.; Ben\u00edtez-King G.; Circadian modulation of neuroplasticity by melatonin: A target in the treatment of depression. Br J Pharmacol 2018,175(16),3200-3208","journal-title":"Br J Pharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2174\/157015910792246209","volume":"8","author":"Cardinali D.P.","year":"2010","unstructured":"Cardinali D.P.; Furio A.M.; Brusco L.I.; Clinical aspects of melatonin intervention in Alzheimer\u2019s disease progression. Curr Neuropharmacol 2010,8(3),218-227","journal-title":"Curr Neuropharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/antiox3020245","volume":"3","author":"Cardinali D.P.","year":"2014","unstructured":"Cardinali D.P.; Vigo D.E.; Olivar N.; Vidal M.F.; Brusco L.I.; Melatonin therapy in patients with Alzheimer\u2019s disease. Antioxidants 2014,3(2),245-277","journal-title":"Antioxidants"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2869.1995.tb00145.x","volume":"4","author":"Moe K.E.","year":"1995","unstructured":"Moe K.E.; Vitiello M.V.; Larsen L.H.; Prinz P.N.; Symposium: Cognitive processes and sleep disturbances: Sleep\/wake patterns in Alzheimer\u2019s disease: relationships with cognition and function. J Sleep Res 1995,4(1),15-20","journal-title":"J Sleep Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuron.2004.08.031","volume":"44","author":"Walker M.P.","year":"2004","unstructured":"Walker M.P.; Stickgold R.; Sleep-dependent learning and memory consolidation. Neuron 2004,44(1),121-133","journal-title":"Neuron"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0006-3223(97)00510-6","volume":"45","author":"Mishima K.","year":"1999","unstructured":"Mishima K.; Tozawa T.; Satoh K.; Matsumoto Y.; Hishikawa Y.; Okawa M.; Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer\u2019s type with disturbed sleep-waking. Biol Psychiatry 1999,45(4),417-421","journal-title":"Biol Psychiatry"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0006-3223(98)00255-8","volume":"45","author":"Ohashi Y.","year":"1999","unstructured":"Ohashi Y.; Okamoto N.; Uchida K.; Iyo M.; Mori N.; Morita Y.; Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer\u2019s type. Biol Psychiatry 1999,45(12),1646-1652","journal-title":"Biol Psychiatry"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/0006-8993(96)00086-8","volume":"717","author":"Uchida K.","year":"1996","unstructured":"Uchida K.; Okamoto N.; Ohara K.; Morita Y.; Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brain Res 1996,717(1-2),154-159","journal-title":"Brain Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1272\/jnms.70.334","volume":"70","author":"Asayama K.","year":"2003","unstructured":"Asayama K.; Yamadera H.; Ito T.; Suzuki H.; Kudo Y.; Endo S.; Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch 2003,70(4),334-341","journal-title":"J Nippon Med Sch"},{"key":"ref=16","first-page":"947","volume":"9","author":"Wade A.G.","year":"2014","unstructured":"Wade A.G.; Farmer M.; Harari G.; Fund N.; Laudon M.; Nir T.; Frydman-Marom A.; Zisapel N.; Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer\u2019s disease: A 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging 2014,9,947-961","journal-title":"Clin Interv Aging"},{"key":"ref=17","first-page":"56","volume":"23","author":"Gao Q.W.","year":"2009","unstructured":"Gao Q.W.; Lio Y.; Luo G.Q.; Xiang W.; Peng K.R.; Effect of melatonin on mild Alzheimer\u2019s disease in elderly male patients. Parct Geriatr 2009,23(1),56-58","journal-title":"Parct Geriatr"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/sleep\/26.7.893","volume":"26","author":"Singer C.","year":"2003","unstructured":"Singer C.; Tractenberg R.E.; Kaye J.; Schafer K.; Gamst A.; Grundman M.; Thomas R.; Thal L.J.; A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer\u2019s disease. Sleep 2003,26(7),893-901","journal-title":"Sleep"},{"key":"ref=19","first-page":"CD009178","author":"McCleery J.","year":"2014","unstructured":"McCleery J.; Cohen D.A.; Sharpley A.L.; Pharmacotherapies for sleep disturbances in Alzheimer\u2019s disease. Cochrane Database Syst Rev 2014(3),CD009178","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=20","first-page":"CD009178","volume":"11","author":"McCleery J.","year":"2016","unstructured":"McCleery J.; Cohen D.A.; Sharpley A.L.; Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev 2016,11,CD009178","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/gps.4571","volume":"32","author":"Wang Y.Y.","year":"2017","unstructured":"Wang Y.Y.; Zheng W.; Ng C.H.; Ungvari G.S.; Wei W.; Xiang Y.T.; Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer\u2019s disease. Int J Geriatr Psychiatry 2017,32(1),50-57","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/1533317514568005","volume":"30","author":"Xu J.","year":"2015","unstructured":"Xu J.; Wang L.L.; Dammer E.B.; Li C.B.; Xu G.; Chen S.D.; Wang G.; Melatonin for sleep disorders and cognition in dementia: A meta-analysis of randomized controlled trials. Am J Alzheimers Dis Other Demen 2015,30(5),439-447","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"ref=23","first-page":"CD009178","volume":"11","author":"McCleery J.","year":"2020","unstructured":"McCleery J.; Sharpley A.L.; Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev 2020,11,CD009178","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.neubiorev.2021.04.034","volume":"127","author":"Sumsuzzman D.M.","year":"2021","unstructured":"Sumsuzzman D.M.; Choi J.; Jin Y.; Hong Y.; Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer\u2019s disease and insomnia: A systematic review and meta-analysis of randomized controlled trials. Neurosci Biobehav Rev 2021,127,459-473","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.smrv.2004.06.004","volume":"9","author":"Brzezinski A.","year":"2005","unstructured":"Brzezinski A.; Vangel M.G.; Wurtman R.J.; Norrie G.; Zhdanova I.; Ben-Shushan A.; Ford I.; Effects of exogenous melatonin on sleep: A meta-analysis. Sleep Med Rev 2005,9(1),41-50","journal-title":"Sleep Med Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1136\/bmj.38731.532766.F6","volume":"332","author":"Buscemi N.","year":"2006","unstructured":"Buscemi N.; Vandermeer B.; Hooton N.; Pandya R.; Tjosvold L.; Hartling L.; Vohra S.; Klassen T.P.; Baker G.; Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: Meta-analysis. BMJ 2006,332(7538),385-393","journal-title":"BMJ"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/sleep\/20.10.908","volume":"20","author":"Sack R.L.","year":"1997","unstructured":"Sack R.L.; Hughes R.J.; Edgar D.M.; Lewy A.J.; Sleep-promoting effects of melatonin: At what dose, in whom, under what conditions, and by what mechanisms? Sleep 1997,20(10),908-915","journal-title":"Sleep"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"101235","DOI":"10.1016\/j.smrv.2019.101235","volume":"50","author":"Yang C.P.","year":"2020","unstructured":"Yang C.P.; Tseng P.T.; Pei-Chen C.J.; Su H.; Satyanarayanan S.K.; Su K.P.; Melatonergic agents in the prevention of delirium: A network meta-analysis of randomized controlled trials. Sleep Med Rev 2020,50,101235","journal-title":"Sleep Med Rev"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0140-6736(15)61478-7","volume":"386","author":"Higgins J.P.","year":"2015","unstructured":"Higgins J.P.; Welton N.J.; Network meta-analysis: A norm for comparative effectiveness? Lancet 2015,386(9994),628-630","journal-title":"Lancet"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S0140-6736(19)33178-2","volume":"395","author":"Naci H.","year":"2020","unstructured":"Naci H.; Salcher-Konrad M.; Kesselheim A.S.; Wieseler B.; Rochaix L.; Redberg R.F.; Salanti G.; Jackson E.; Garner S.; Stroup T.S.; Cipriani A.; Generating comparative evidence on new drugs and devices before approval. Lancet 2020,395(10228),986-997","journal-title":"Lancet"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"Page M.J.","year":"2021","unstructured":"Page M.J.; McKenzie J.E.; Bossuyt P.M.; Boutron I.; Hoffmann T.C.; Mulrow C.D.; Shamseer L.; Tetzlaff J.M.; Akl E.A.; Brennan S.E.; Chou R.; Glanville J.; Grimshaw J.M.; Hr\u00f3bjartsson A.; Lalu M.M.; Li T.; Loder E.W.; Mayo-Wilson E.; McDonald S.; McGuinness L.A.; Stewart L.A.; Thomas J.; Tricco A.C.; Welch V.A.; Whiting P.; Moher D.; The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021,372(71),n71","journal-title":"BMJ"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"Shea B.J.","year":"2017","unstructured":"Shea B.J.; Reeves B.C.; Wells G.; Thuku M.; Hamel C.; Moran J.; Moher D.; Tugwell P.; Welch V.; Kristjansson E.; Henry D.A.; AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017,358,j4008","journal-title":"BMJ"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/NSS.S76706","volume":"8","author":"Urrestarazu E.","year":"2016","unstructured":"Urrestarazu E.; Iriarte J.; Clinical management of sleep disturbances in Alzheimer\u2019s disease: Current and emerging strategies. Nat Sci Sleep 2016,8,21-33","journal-title":"Nat Sci Sleep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10072-015-2357-0","volume":"37","author":"Zhang W.","year":"2016","unstructured":"Zhang W.; Chen X.Y.; Su S.W.; Jia Q.Z.; Ding T.; Zhu Z.N.; Zhang T.; Exogenous melatonin for sleep disorders in neurodegenerative diseases: A meta-analysis of randomized clinical trials. Neurol Sci 2016,37(1),57-65","journal-title":"Neurol Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.trci.2019.07.004","volume":"5","author":"Watanabe M.","year":"2019","unstructured":"Watanabe M.; Nakamura Y.; Yoshiyama Y.; Kagimura T.; Kawaguchi H.; Matsuzawa H.; Tachibana Y.; Nishimura K.; Kubota N.; Kobayashi M.; Saito T.; Tamura K.; Sato T.; Takahashi M.; Homma A.; Analyses of natural courses of Japanese patients with Alzheimer\u2019s disease using placebo data from placebo-controlled, randomized clinical trials: Japanese study on the estimation of clinical course of Alzheimer\u2019s disease. Alzheimers Dement (N Y) 2019,5(1),398-408","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e16091","DOI":"10.1097\/MD.0000000000016091","volume":"98","author":"Cui C.C.","year":"2019","unstructured":"Cui C.C.; Sun Y.; Wang X.Y.; Zhang Y.; Xing Y.; The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: A network meta-analysis. Medicine (Baltimore) 2019,98(27),e16091","journal-title":"Medicine (Baltimore)"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"w20093","DOI":"10.4414\/smw.2019.20093","volume":"149","author":"Glinz D.","year":"2019","unstructured":"Glinz D.; Gloy V.L.; Monsch A.U.; Kressig R.W.; Patel C.; McCord K.A.; Ademi Z.; Tomonaga Y.; Schwenkglenks M.; Bucher H.C.; Raatz H.; Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer\u2019s disease: a meta-analysis. Swiss Med Wkly 2019,149,w20093","journal-title":"Swiss Med Wkly"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fnins.2019.00472","volume":"13","author":"Li D.D.","year":"2019","unstructured":"Li D.D.; Zhang Y.H.; Zhang W.; Zhao P.; Meta-Analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease. Front Neurosci 2019,13,472","journal-title":"Front Neurosci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40266-019-00648-x","volume":"36","author":"Thancharoen O.","year":"2019","unstructured":"Thancharoen O.; Limwattananon C.; Waleekhachonloet O.; Rattanachotphanit T.; Limwattananon P.; Limpawattana P.; Ginkgo biloba Extract (EGb761), Cholinesterase inhibitors, and memantine for the treatment of mild-to-moderate Alzheimer\u2019s disease: A network meta-analysis. Drugs Aging 2019,36(5),435-452","journal-title":"Drugs Aging"},{"key":"ref=40","first-page":"CD003154","volume":"3","author":"McShane R.","year":"2019","unstructured":"McShane R.; Westby M.J.; Roberts E.; Minakaran N.; Schneider L.; Farrimond L.E.; Maayan N.; Ware J.; Debarros J.; Memantine for dementia. Cochrane Database Syst Rev 2019,3,CD003154","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13195-018-0457-9","volume":"10","author":"Dou K.X.","year":"2018","unstructured":"Dou K.X.; Tan M.S.; Tan C.C.; Cao X.P.; Hou X.H.; Guo Q.H.; Tan L.; Mok V.; Yu J.T.; Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer\u2019s disease: A network meta-analysis of 41 randomized controlled trials. Alzheimers Res Ther 2018,10(1),126","journal-title":"Alzheimers Res Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"CD001190","DOI":"10.1002\/14651858.CD001190.pub3","volume":"6","author":"Birks J.S.","year":"2018","unstructured":"Birks J.S.; Harvey R.J.; Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev 2018,6(6),CD001190","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=43","first-page":"57","volume":"5","author":"Koola M.M.","year":"2018","unstructured":"Koola M.M.; Nikiforuk A.; Pillai A.; Parsaik A.K.; Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer\u2019s disease: Critical dissection with an emphasis on kynurenic acid and mismatch negativity. J Geriatr Care Res 2018,5(2),57-67","journal-title":"J Geriatr Care Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.2147\/NDT.S142839","volume":"13","author":"Kishi T.","year":"2017","unstructured":"Kishi T.; Matsunaga S.; Iwata N.; The effects of memantine on behavioral disturbances in patients with Alzheimer\u2019s disease: A meta-analysis. Neuropsychiatr Dis Treat 2017,13,1909-1928","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/obr.12835","volume":"20","author":"Hsieh M.T.","year":"2019","unstructured":"Hsieh M.T.; Tseng P.T.; Wu Y.C.; Tu Y.K.; Wu H.C.; Hsu C.W.; Lei W.T.; Stubbs B.; Carvalho A.F.; Liang C.S.; Yeh T.C.; Chen T.Y.; Chu C.S.; Li J.C.; Yu C.L.; Chen Y.W.; Li D.J.; Effects of different pharmacologic smoking cessation treatments on body weight changes and success rates in patients with nicotine dependence: A network meta-analysis. Obes Rev 2019,20(6),895-905","journal-title":"Obes Rev"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"276520","DOI":"10.5402\/2012\/276520","volume":"2012","author":"Tu Y.K.","year":"2012","unstructured":"Tu Y.K.; Faggion C.M.; A primer on network meta-analysis for dental research. ISRN Dent 2012,2012,276520","journal-title":"ISRN Dent"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/jamapsychiatry.2018.4365","volume":"76","author":"Wu Y.C.","year":"2019","unstructured":"Wu Y.C.; Tseng P.T.; Tu Y.K.; Hsu C.Y.; Liang C.S.; Yeh T.C.; Chen T.Y.; Chu C.S.; Matsuoka Y.J.; Stubbs B.; Carvalho A.F.; Wada S.; Lin P.Y.; Chen Y.W.; Su K.P.; Association of delirium response and safety of pharmacological interventions for the management and prevention of delirium: A network meta-analysis. JAMA Psychiatry 2019,76(5),526-535","journal-title":"JAMA Psychiatry"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1177\/0022034519870466","volume":"98","author":"Zeng B.S.","year":"2019","unstructured":"Zeng B.S.; Lin S.Y.; Tu Y.K.; Wu Y.C.; Stubbs B.; Liang C.S.; Yeh T.C.; Chen T.Y.; Carvalho A.F.; Lin P.Y.; Lei W.T.; Hsu C.W.; Chen Y.W.; Tseng P.T.; Chen C.H.; Prevention of postdental procedure bacteremia: A network meta-analysis. J Dent Res 2019,98(11),1204-1210","journal-title":"J Dent Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"l5919","DOI":"10.1136\/bmj.l5919","volume":"367","author":"Huang S.W.","year":"2019","unstructured":"Huang S.W.; Tsai C.Y.; Tseng C.S.; Shih M.C.; Yeh Y.C.; Chien K.L.; Pu Y.S.; Tu Y.K.; Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: Systematic review and network meta-analysis. BMJ 2019,367,l5919","journal-title":"BMJ"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e12663","DOI":"10.1111\/jpi.12663","volume":"69","author":"Tseng P.T.","year":"2020","unstructured":"Tseng P.T.; Yang C.P.; Su K.P.; Chen T.Y.; Wu Y.C.; Tu Y.K.; Lin P.Y.; Stubbs B.; Carvalho A.F.; Matsuoka Y.J.; Li D.J.; Liang C.S.; Hsu C.W.; Chen Y.W.; Shiue Y.L.; The association between melatonin and episodic migraine: A pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. J Pineal Res 2020,69(2),e12663","journal-title":"J Pineal Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"101080","DOI":"10.1016\/j.eclinm.2021.101080","volume":"39","author":"Chen J.J.","year":"2021","unstructured":"Chen J.J.; Chen Y.W.; Zeng B.Y.; Hung C.M.; Zeng B.S.; Stubbs B.; Carvalho A.F.; Thompson T.; Roerecke M.; Su K.P.; Tu Y.K.; Wu Y.C.; Smith L.; Chen T.Y.; Lin P.Y.; Liang C.S.; Hsu C.W.; Hsu S.P.; Kuo H.C.; Wu M.K.; Tseng P.T.; Efficacy of pharmacologic treatment in tinnitus patients without specific or treatable origin: A network meta-analysis of randomised controlled trials. Eclini Med 2021,39,101080","journal-title":"Eclini Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jamaoto.2020.1497","volume":"146","author":"Chen J.J.","year":"2020","unstructured":"Chen J.J.; Zeng B.S.; Wu C.N.; Stubbs B.; Carvalho A.F.; Brunoni A.R.; Su K.P.; Tu Y.K.; Wu Y.C.; Chen T.Y.; Lin P.Y.; Liang C.S.; Hsu C.W.; Hsu S.P.; Kuo H.C.; Chen Y.W.; Tseng P.T.; Li C.T.; Association of central noninvasive brain stimulation interventions with efficacy and safety in tinnitus management: A meta-analysis. JAMA Otolaryngol Head Neck Surg 2020,146(9),801-809","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"101469","DOI":"10.1016\/j.smrv.2021.101469","volume":"57","author":"Cheng Y.S.","year":"2021","unstructured":"Cheng Y.S.; Tseng P.T.; Wu M.K.; Tu Y.K.; Wu Y.C.; Li D.J.; Chen T.Y.; Su K.P.; Stubbs B.; Carvalho A.F.; Lin P.Y.; Matsuoka Y.J.; Chen Y.W.; Sun C.K.; Shiue Y.L.; Pharmacologic and hormonal treatments for menopausal sleep disturbances: A network meta-analysis of 43 randomized controlled trials and 32,271 menopausal women. Sleep Med Rev 2021,57,101469","journal-title":"Sleep Med Rev"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"E196","DOI":"10.1503\/jpn.190122","volume":"46","author":"Cheng Y.S.","year":"2021","unstructured":"Cheng Y.S.; Tseng P.T.; Wu Y.C.; Tu Y.K.; Wu C.K.; Hsu C.W.; Lei W.T.; Li D.J.; Chen T.Y.; Stubbs B.; Carvalho A.F.; Liang C.S.; Yeh T.C.; Chu C.S.; Chen Y.W.; Lin P.Y.; Wu M.K.; Sun C.K.; Therapeutic benefits of pharmacologic and nonpharmacologic treatments for depressive symptoms after traumatic brain injury: A systematic review and network meta-analysis. J Psychiatry Neurosci 2021,46(1),E196-E207","journal-title":"J Psychiatry Neurosci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"110488","DOI":"10.1016\/j.jclinane.2021.110488","volume":"75","author":"Wang H.Y.","year":"2021","unstructured":"Wang H.Y.; Chen T.Y.; Li D.J.; Lin P.Y.; Su K.P.; Chiang M.H.; Carvalho A.F.; Stubbs B.; Tu Y.K.; Wu Y.C.; Roerecke M.; Smith L.; Tseng P.T.; Hung K.C.; Association of pharmacological prophylaxis with the risk of pediatric emergence delirium after sevoflurane anesthesia: An updated network meta-analysis. J Clin Anesth 2021,75,110488","journal-title":"J Clin Anesth"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/WAD.0b013e31816653bc","volume":"22","author":"Atri A.","year":"2008","unstructured":"Atri A.; Shaughnessy L.W.; Locascio J.J.; Growdon J.H.; Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008,22(3),209-221","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.archger.2003.12.004","volume":"39","author":"Wlodarczyk J.H.","year":"2004","unstructured":"Wlodarczyk J.H.; Brodaty H.; Hawthorne G.; The relationship between quality of life, Mini-Mental State Examination, and the instrumental activities of daily living in patients with Alzheimer\u2019s disease. Arch Gerontol Geriatr 2004,39(1),25-33","journal-title":"Arch Gerontol Geriatr"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/01.JGP.0000192478.82189.a8","volume":"14","author":"Perneczky R.","year":"2006","unstructured":"Perneczky R.; Wagenpfeil S.; Komossa K.; Grimmer T.; Diehl J.; Kurz A.; Mapping scores onto stages: Mini-mental state examination and clinical dementia rating. Am J Geriatr Psychiatry 2006,14(2),139-144","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/archneur.58.3.449","volume":"58","author":"Doody R.S.","year":"2001","unstructured":"Doody R.S.; Massman P.; Dunn J.K.; A method for estimating progression rates in Alzheimer disease. Arch Neurol 2001,58(3),449-454","journal-title":"Arch Neurol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3233\/JAD-150852","volume":"52","author":"Henneges C.","year":"2016","unstructured":"Henneges C.; Reed C.; Chen Y.F.; Dell\u2019Agnello G.; Lebrec J.; Describing the sequence of cognitive decline in Alzheimer\u2019s disease patients: Results from an observational study. J Alzheimers Dis 2016,52(3),1065-1080","journal-title":"J Alzheimers Dis"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","volume":"11","author":"Mohs R.C.","year":"1997","unstructured":"Mohs R.C.; Knopman D.; Petersen R.C.; Ferris S.H.; Ernesto C.; Grundman M.; Sano M.; Bieliauskas L.; Geldmacher D.; Clark C.; Thal L.J.; Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer\u2019s disease assessment scale that broaden its scope. The Alzheimer\u2019s disease cooperative study. Alzheimer Dis Assoc Disord 1997,11(Suppl. 2),S13-S21","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=62","author":"Higgins J.","year":"2009","unstructured":"Higgins J.; Green S.;  Cochrane handbook for systematic reviews of interventions version 502 2009","journal-title":"Cochrane handbook for systematic reviews of interventions version 502"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"g5630","DOI":"10.1136\/bmj.g5630","volume":"349","author":"Puhan M.A.","year":"2014","unstructured":"Puhan M.A.; Sch\u00fcnemann H.J.; Murad M.H.; Li T.; Brignardello-Petersen R.; Singh J.A.; Kessels A.G.; Guyatt G.H.; Group G.W.; A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014,349(sep24 5),g5630","journal-title":"BMJ"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"Cipriani A.","year":"2018","unstructured":"Cipriani A.; Furukawa T.A.; Salanti G.; Chaimani A.; Atkinson L.Z.; Ogawa Y.; Leucht S.; Ruhe H.G.; Turner E.H.; Higgins J.P.T.; Egger M.; Takeshima N.; Hayasaka Y.; Imai H.; Shinohara K.; Tajika A.; Ioannidis J.P.A.; Geddes J.R.; Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet 2018,391(10128),1357-1366","journal-title":"Lancet"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.1002\/sim.6301","volume":"33","author":"Brockhaus A.C.","year":"2014","unstructured":"Brockhaus A.C.; Bender R.; Skipka G.; The Peto odds ratio viewed as a new effect measure. Stat Med 2014,33(28),4861-4874","journal-title":"Stat Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"e010983","DOI":"10.1136\/bmjopen-2015-010983","volume":"6","author":"Cheng J.","year":"2016","unstructured":"Cheng J.; Pullenayegum E.; Marshall J.K.; Iorio A.; Thabane L.; Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: A simulation study. BMJ Open 2016,6(8),e010983","journal-title":"BMJ Open"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1177\/0272989X14545789","volume":"34","author":"Tu Y.K.","year":"2014","unstructured":"Tu Y.K.; Use of generalized linear mixed models for network meta-analysis. Med Decis Making 2014,34(7),911-918","journal-title":"Med Decis Making"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"Lu G.","year":"2004","unstructured":"Lu G.; Ades A.E.; Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004,23(20),3105-3124","journal-title":"Stat Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/lary.25688","volume":"126","author":"Liu Y.","year":"2016","unstructured":"Liu Y.; Wang W.; Zhang A.B.; Bai X.; Zhang S.; Epley and Semont maneuvers for posterior canal benign paroxysmal positional vertigo: A network meta-analysis. Laryngoscope 2016,126(4),951-955","journal-title":"Laryngoscope"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"e69930","DOI":"10.1371\/journal.pone.0069930","volume":"8","author":"Kontopantelis E.","year":"2013","unstructured":"Kontopantelis E.; Springate D.A.; Reeves D.; A re-analysis of the Cochrane Library data: The dangers of unobserved heterogeneity in meta-analyses. PLoS One 2013,8(7),e69930","journal-title":"PLoS One"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"Salanti G.","year":"2011","unstructured":"Salanti G.; Ades A.E.; Ioannidis J.P.; Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011,64(2),163-171","journal-title":"J Clin Epidemiol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"A324","DOI":"10.1016\/j.jval.2014.08.572","volume":"17","author":"Higgins J.P.","year":"2014","unstructured":"Higgins J.P.; Del Giovane C.; Chaimani A.; Caldwell D.M.; Salanti G.; Evaluating the quality of evidence from a network meta-analysis. Value Health 2014,17(7),A324","journal-title":"Value Health"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"Chaimani A.","year":"2013","unstructured":"Chaimani A.; Higgins J.P.; Mavridis D.; Spyridonos P.; Salanti G.; Graphical tools for network meta-analysis in STATA. PLoS One 2013,8(10),e76654","journal-title":"PLoS One"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"l1079","DOI":"10.1136\/bmj.l1079","volume":"364","author":"Mutz J.","year":"2019","unstructured":"Mutz J.; Vipulananthan V.; Carter B.; Hurlemann R.; Fu C.H.Y.; Young A.H.; Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: Systematic review and network meta-analysis. BMJ 2019,364,l1079","journal-title":"BMJ"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","volume":"326","author":"Altman D.G.","year":"2003","unstructured":"Altman D.G.; Bland J.M.; Interaction revisited: The difference between two estimates. BMJ 2003,326(7382),219","journal-title":"BMJ"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1212\/WNL.57.8.1515","volume":"57","author":"Adair J.C.","year":"2001","unstructured":"Adair J.C.; Knoefel J.E.; Morgan N.; Controlled trial of N-acetylcysteine for patients with probable Alzheimer\u2019s disease. Neurology 2001,57(8),1515-1517","journal-title":"Neurology"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2017.20373","volume":"319","author":"Atri A.","year":"2018","unstructured":"Atri A.; Fr\u00f6lich L.; Ballard C.; Tariot P.N.; Molinuevo J.L.; Boneva N.; Windfeld K.; Raket L.L.; Cummings J.L.; Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: Three randomized clinical trials. JAMA 2018,319(2),130-142","journal-title":"JAMA"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3233\/JAD-160758","volume":"57","author":"Bloniecki V.","year":"2017","unstructured":"Bloniecki V.; Aarsland D.; Blennow K.; Cummings J.; Falahati F.; Winblad B.; Freund-Levi Y.; Effects of risperidone and galantamine treatment on Alzheimer\u2019s disease biomarker levels in cerebrospinal fluid. J Alzheimers Dis 2017,57(2),387-393","journal-title":"J Alzheimers Dis"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1185\/030079905X56565","volume":"21","author":"Bullock R.","year":"2005","unstructured":"Bullock R.; Touchon J.; Bergman H.; Gambina G.; He Y.; Rapatz G.; Nagel J.; Lane R.; Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer\u2019s disease over a 2-year period. Curr Med Res Opin 2005,21(8),1317-1327","journal-title":"Curr Med Res Opin"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/gps.1856","volume":"23","author":"Connelly P.J.","year":"2008","unstructured":"Connelly P.J.; Prentice N.P.; Cousland G.; Bonham J.; A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer\u2019s disease. Int J Geriatr Psychiatry 2008,23(2),155-160","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000340056","volume":"33","author":"Cummings J.","year":"2012","unstructured":"Cummings J.; Froelich L.; Black S.E.; Bakchine S.; Bellelli G.; Molinuevo J.L.; Kressig R.W.; Downs P.; Caputo A.; Strohmaier C.; Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm\u00b2) in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 2012,33(5),341-353","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.sleep.2016.07.006","volume":"23","author":"Devore E.E.","year":"2016","unstructured":"Devore E.E.; Harrison S.L.; Stone K.L.; Holton K.F.; Barrett-Connor E.; Ancoli-Israel S.; Yaffe K.; Ensrud K.; Cawthon P.M.; Redline S.; Orwoll E.; Schernhammer E.S.; Association of urinary melatonin levels and aging-related outcomes in older men. Sleep Med 2016,23,73-80","journal-title":"Sleep Med"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","volume":"372","author":"Doody R.S.","year":"2008","unstructured":"Doody R.S.; Gavrilova S.I.; Sano M.; Thomas R.G.; Aisen P.S.; Bachurin S.O.; Seely L.; Hung D.; Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer\u2019s disease: A randomised, double-blind, placebo-controlled study. Lancet 2008,372(9634),207-215","journal-title":"Lancet"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1532-5415.2007.01543.x","volume":"56","author":"Dowling G.A.","year":"2008","unstructured":"Dowling G.A.; Burr R.L.; Van Someren E.J.; Hubbard E.M.; Luxenberg J.S.; Mastick J.; Cooper B.A.; Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer\u2019s disease. J Am Geriatr Soc 2008,56(2),239-246","journal-title":"J Am Geriatr Soc"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jclinane.2017.03.023","volume":"39","author":"Fan Y.","year":"2017","unstructured":"Fan Y.; Yuan L.; Ji M.; Yang J.; Gao D.; The effect of melatonin on early postoperative cognitive decline in elderly patients undergoing hip arthroplasty: A randomized controlled trial. J Clin Anesth 2017,39,77-81","journal-title":"J Clin Anesth"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/jnnp.2006.099424","volume":"78","author":"Feldman H.H.","year":"2007","unstructured":"Feldman H.H.; Lane R.; Study G.; Rivastigmine: A placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 2007,78(10),1056-1063","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3233\/JAD-2011-101554","volume":"24","author":"Fr\u00f6lich L.","year":"2011","unstructured":"Fr\u00f6lich L.; Ashwood T.; Nilsson J.; Eckerwall G.; Sirocco I.; Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer\u2019s disease: A phase IIb dose-finding study. J Alzheimers Dis 2011,24(2),363-374","journal-title":"J Alzheimers Dis"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/JAD-180595","volume":"67","author":"Fr\u00f6lich L.","year":"2019","unstructured":"Fr\u00f6lich L.; Atri A.; Ballard C.; Tariot P.N.; Molinuevo J.L.; Boneva N.; Geist M.A.; Raket L.L.; Cummings J.L.; Open-label, multicenter, phase III extension study of idalopirdine as adjunctive to donepezil for the treatment of mild-moderate Alzheimer\u2019s disease. J Alzheimers Dis 2019,67(1),303-313","journal-title":"J Alzheimers Dis"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13195-018-0368-9","volume":"10","author":"Fullerton T.","year":"2018","unstructured":"Fullerton T.; Binneman B.; David W.; Delnomdedieu M.; Kupiec J.; Lockwood P.; Mancuso J.; Miceli J.; Bell J.; A phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer\u2019s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil. Alzheimers Res Ther 2018,10(1),38","journal-title":"Alzheimers Res Ther"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/BF03324897","volume":"21","author":"Garz\u00f3n C.","year":"2009","unstructured":"Garz\u00f3n C.; Guerrero J.M.; Aramburu O.; Guzm\u00e1n T.; Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: A randomized, double-blind, placebo-controlled study. Aging Clin Exp Res 2009,21(1),38-42","journal-title":"Aging Clin Exp Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13195-016-0210-1","volume":"8","author":"Gault L.M.","year":"2016","unstructured":"Gault L.M.; Lenz R.A.; Ritchie C.W.; Meier A.; Othman A.A.; Tang Q.; Berry S.; Pritchett Y.; Robieson W.Z.; ABT-126 monotherapy in mild-to-moderate Alzheimer\u2019s dementia: Randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Alzheimers Res Ther 2016,8(1),44","journal-title":"Alzheimers Res Ther"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.trci.2015.06.001","volume":"1","author":"Gault L.M.","year":"2015","unstructured":"Gault L.M.; Ritchie C.W.; Robieson W.Z.; Pritchett Y.; Othman A.A.; Lenz R.A.; A phase 2 randomized, controlled trial of the \u03b17 agonist ABT-126 in mild-to-moderate Alzheimer\u2019s dementia. Alzheimers Dement (N Y) 2015,1(1),81-90","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/JGP.0b013e318187de18","volume":"17","author":"Gehrman P.R.","year":"2009","unstructured":"Gehrman P.R.; Connor D.J.; Martin J.L.; Shochat T.; Corey-Bloom J.; Ancoli-Israel S.; Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatry 2009,17(2),166-169","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/WAD.0000000000000261","volume":"32","author":"Grossberg G.T.","year":"2018","unstructured":"Grossberg G.T.; Alva G.; Hendrix S.; Ellison N.; Kane M.C.; Edwards J.; Memantine E.R.; Memantine ER maintains patient response in moderate to severe Alzheimer\u2019s disease: Post hoc analyses from a randomized, controlled, clinical trial of patients treated with cholinesterase inhibitors. Alzheimer Dis Assoc Disord 2018,32(3),173-178","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/1099-1166(200101)16:1<106::AID-GPS288>3.0.CO;2-9","volume":"16","author":"Haffmans P.M.","year":"2001","unstructured":"Haffmans P.M.; Sival R.C.; Lucius S.A.; Cats Q.; van Gelder L.; Bright light therapy and melatonin in motor restless behaviour in dementia: A placebo-controlled study. Int J Geriatr Psychiatry 2001,16(1),106-110","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3233\/JAD-140291","volume":"42","author":"Haig G.M.","year":"2014","unstructured":"Haig G.M.; Pritchett Y.; Meier A.; Othman A.A.; Hall C.; Gault L.M.; Lenz R.A.; A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer\u2019s dementia. J Alzheimers Dis 2014,42(3),959-971","journal-title":"J Alzheimers Dis"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.npbr.2017.04.002","volume":"24","author":"Hamdieh M.","year":"2017","unstructured":"Hamdieh M.; Abbasinazari M.; Badri T.; Saberi-Isfeedvajani M.; Arzani G.; The impact of melatonin on the alleviation of cognitive impairment during electroconvulsive therapy: A double-blind controlled trial. Neurol Psychiatry Brain Res 2017,24,30-34","journal-title":"Neurol Psychiatry Brain Res"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3233\/JAD-180159","volume":"63","author":"Hong Y.J.","year":"2018","unstructured":"Hong Y.J.; Choi S.H.; Jeong J.H.; Park K.W.; Na H.R.; Effectiveness of anti-dementia drugs in extremely severe Alzheimer\u2019s disease: A 12-week, multicenter, randomized, single-blind study. J Alzheimers Dis 2018,63(3),1035-1044","journal-title":"J Alzheimers Dis"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13195-019-0492-1","volume":"11","author":"Hong Y.J.","year":"2019","unstructured":"Hong Y.J.; Han H.J.; Youn Y.C.; Park K.W.; Yang D.W.; Kim S.; Kim H.J.; Kim J.E.; Lee J.H.; Safety and tolerability of donepezil 23\u2009mg with or without intermediate dose titration in patients with Alzheimer\u2019s disease taking donepezil 10\u2009mg: A multicenter, randomized, open-label, parallel-design, three-arm, prospective trial. Alzheimers Res Ther 2019,11(1),37","journal-title":"Alzheimers Res Ther"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"Howard R.","year":"2012","unstructured":"Howard R.; McShane R.; Lindesay J.; Ritchie C.; Baldwin A.; Barber R.; Burns A.; Dening T.; Findlay D.; Holmes C.; Hughes A.; Jacoby R.; Jones R.; Jones R.; McKeith I.; Macharouthu A.; O\u2019Brien J.; Passmore P.; Sheehan B.; Juszczak E.; Katona C.; Hills R.; Knapp M.; Ballard C.; Brown R.; Banerjee S.; Onions C.; Griffin M.; Adams J.; Gray R.; Johnson T.; Bentham P.; Phillips P.; Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N Engl J Med 2012,366(10),893-903","journal-title":"N Engl J Med"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3233\/JAD-180684","volume":"67","author":"Huisa B.N.","year":"2019","unstructured":"Huisa B.N.; Thomas R.G.; Jin S.; Oltersdorf T.; Taylor C.; Feldman H.H.; Memantine and acetylcholinesterase inhibitor use in Alzheimer\u2019s disease clinical trials: Potential for confounding by indication. J Alzheimers Dis 2019,67(2),707-713","journal-title":"J Alzheimers Dis"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.amjmed.2018.04.009","volume":"131","author":"Jaiswal S.J.","year":"2018","unstructured":"Jaiswal S.J.; McCarthy T.J.; Wineinger N.E.; Kang D.Y.; Song J.; Garcia S.; van Niekerk C.J.; Lu C.Y.; Loeks M.; Owens R.L.; Melatonin and sleep in preventing hospitalized delirium: A randomized clinical trial. Am J Med 2018,131(9),1110-1117.e4","journal-title":"Am J Med"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2165\/00023210-200620040-00005","volume":"20","author":"Johannsen P.","year":"2006","unstructured":"Johannsen P.; Salmon E.; Hampel H.; Xu Y.; Richardson S.; Qvitzau S.; Schindler R.; Group A.S.; Assessing therapeutic efficacy in a progressive disease: A study of donepezil in Alzheimer\u2019s disease. CNS Drugs 2006,20(4),311-325","journal-title":"CNS Drugs"},{"key":"ref=104","first-page":"1875","volume":"15","author":"Ma Y.","year":"2018","unstructured":"Ma Y.; Ji J.; Li G.; Yang S.; Pan S.; Effects of donepezil on cognitive functions and the expression level of \u03b2-amyloid in peripheral blood of patients with Alzheimer\u2019s disease. Exp Ther Med 2018,15(2),1875-1878","journal-title":"Exp Ther Med"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2174\/156720510791383831","volume":"7","author":"Maher-Edwards G.","year":"2010","unstructured":"Maher-Edwards G.; Zvartau-Hind M.; Hunter A.J.; Gold M.; Hopton G.; Jacobs G.; Davy M.; Williams P.; Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer\u2019s disease. Curr Alzheimer Res 2010,7(5),374-385","journal-title":"Curr Alzheimer Res"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.sleep.2019.04.018","volume":"63","author":"Manni R.","year":"2019","unstructured":"Manni R.; Cremascoli R.; Perretti C.; De Icco R.; Picascia M.; Ghezzi C.; Cerri S.; Sinforiani E.; Terzaghi M.; Evening melatonin timing secretion in real life conditions in patients with Alzheimer disease of mild to moderate severity. Sleep Med 2019,63,122-126","journal-title":"Sleep Med"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/JGP.0b013e3181557b47","volume":"15","author":"Mintzer J.E.","year":"2007","unstructured":"Mintzer J.E.; Tune L.E.; Breder C.D.; Swanink R.; Marcus R.N.; McQuade R.D.; Forbes A.; Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: A multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry 2007,15(11),918-931","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/ene.13872","volume":"26","author":"Montero-Odasso M.","year":"2019","unstructured":"Montero-Odasso M.; Speechley M.; Chertkow H.; Sarquis-Adamson Y.; Wells J.; Borrie M.; Vanderhaeghe L.; Zou G.Y.; Fraser S.; Bherer L.; Muir-Hunter S.W.; Donepezil for gait and falls in mild cognitive impairment: A randomized controlled trial. Eur J Neurol 2019,26(4),651-659","journal-title":"Eur J Neurol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jama.283.8.1007","volume":"283","author":"Mulnard R.A.","year":"2000","unstructured":"Mulnard R.A.; Cotman C.W.; Kawas C.; van Dyck C.H.; Sano M.; Doody R.; Koss E.; Pfeiffer E.; Jin S.; Gamst A.; Grundman M.; Thomas R.; Thal L.J.; Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer\u2019s Disease Cooperative Study. JAMA 2000,283(8),1007-1015","journal-title":"JAMA"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1517\/14656566.2014.902446","volume":"15","author":"Nakamura Y.","year":"2014","unstructured":"Nakamura Y.; Kitamura S.; Homma A.; Shiosakai K.; Matsui D.; Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer\u2019s disease: Results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. Expert Opin Pharmacother 2014,15(7),913-925","journal-title":"Expert Opin Pharmacother"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa050151","volume":"352","author":"Petersen R.C.","year":"2005","unstructured":"Petersen R.C.; Thomas R.G.; Grundman M.; Bennett D.; Doody R.; Ferris S.; Galasko D.; Jin S.; Kaye J.; Levey A.; Pfeiffer E.; Sano M.; van Dyck C.H.; Thal L.J.; Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005,352(23),2379-2388","journal-title":"N Engl J Med"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/archneur.63.1.49","volume":"63","author":"Reisberg B.","year":"2006","unstructured":"Reisberg B.; Doody R.; St\u00f6ffler A.; Schmitt F.; Ferris S.; M\u00f6bius H.J.; A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006,63(1),49-54","journal-title":"Arch Neurol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","volume":"71","author":"Rockwood K.","year":"2001","unstructured":"Rockwood K.; Mintzer J.; Truyen L.; Wessel T.; Wilkinson D.; Effects of a flexible galantamine dose in Alzheimer\u2019s disease: A randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001,71(5),589-595","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","volume":"158","author":"Rogers S.L.","year":"1998","unstructured":"Rogers S.L.; Doody R.S.; Mohs R.C.; Friedhoff L.T.; Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998,158(9),1021-1031","journal-title":"Arch Intern Med"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1179\/1476830511Y.0000000032","volume":"15","author":"Rondanelli M.","year":"2012","unstructured":"Rondanelli M.; Opizzi A.; Faliva M.; Mozzoni M.; Antoniello N.; Cazzola R.; Savar\u00e8 R.; Cerutti R.; Grossi E.; Cestaro B.; Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment. Nutr Neurosci 2012,15(2),46-54","journal-title":"Nutr Neurosci"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","volume":"77","author":"Sano M.","year":"2011","unstructured":"Sano M.; Bell K.L.; Galasko D.; Galvin J.E.; Thomas R.G.; van Dyck C.H.; Aisen P.S.; A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011,77(6),556-563","journal-title":"Neurology"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2165\/11310960-000000000-00000","volume":"24","author":"Santoro A.","year":"2010","unstructured":"Santoro A.; Siviero P.; Minicuci N.; Bellavista E.; Mishto M.; Olivieri F.; Marchegiani F.; Chiamenti A.M.; Benussi L.; Ghidoni R.; Nacmias B.; Bagnoli S.; Ginestroni A.; Scarpino O.; Feraco E.; Gianni W.; Cruciani G.; Paganelli R.; Di Iorio A.; Scognamiglio M.; Grimaldi L.M.; Gabelli C.; Sorbi S.; Binetti G.; Crepaldi G.; Franceschi C.; Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer\u2019s disease: a prospective, observational study. CNS Drugs 2010,24(2),163-176","journal-title":"CNS Drugs"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/gps.760","volume":"17","author":"Serfaty M.","year":"2002","unstructured":"Serfaty M.; Kennell-Webb S.; Warner J.; Blizard R.; Raven P.; Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry 2002,17(12),1120-1127","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/ana.10292","volume":"52","author":"Simons M.","year":"2002","unstructured":"Simons M.; Schw\u00e4rzler F.; L\u00fctjohann D.; von Bergmann K.; Beyreuther K.; Dichgans J.; Wormstall H.; Hartmann T.; Schulz J.B.; Treatment with simvastatin in normocholesterolemic patients with Alzheimer\u2019s disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002,52(3),346-350","journal-title":"Ann Neurol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12877-019-1122-2","volume":"19","author":"Soler A.","year":"2019","unstructured":"Soler A.; Amer G.; Leiva A.; Ripoll J.; Llorente M.A.; Leiva A.; Taltavull J.M.; Molina R.; Llobera J.; Continuation versus discontinuation of treatment for severe dementia: Randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM). BMC Geriatr 2019,19(1),101","journal-title":"BMC Geriatr"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1212\/01.WNL.0000096376.03678.C1","volume":"61","author":"Thal L.J.","year":"2003","unstructured":"Thal L.J.; Grundman M.; Berg J.; Ernstrom K.; Margolin R.; Pfeiffer E.; Weiner M.F.; Zamrini E.; Thomas R.G.; Idebenone treatment fails to slow cognitive decline in Alzheimer\u2019s disease. Neurology 2003,61(11),1498-1502","journal-title":"Neurology"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.54.11.2061","volume":"54","author":"Wang P.N.","year":"2000","unstructured":"Wang P.N.; Liao S.Q.; Liu R.S.; Liu C.Y.; Chao H.T.; Lu S.R.; Yu H.Y.; Wang S.J.; Liu H.C.; Effects of estrogen on cognition, mood, and cerebral blood flow in AD: A controlled study. Neurology 2000,54(11),2061-2066","journal-title":"Neurology"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1212\/01.wnl.0000281847.17519.e0","volume":"69","author":"Winblad B.","year":"2007","unstructured":"Winblad B.; Grossberg G.; Fr\u00f6lich L.; Farlow M.; Zechner S.; Nagel J.; Lane R.; IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007,69(4)(Suppl. 1),S14-S22","journal-title":"Neurology"},{"key":"ref=124","first-page":"941","volume":"82","author":"Zhang Z.","year":"2002","unstructured":"Zhang Z.; Wang X.; Chen Q.; Shu L.; Wang J.; Shan G.; [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]. Zhonghua Yi Xue Za Zhi 2002,82(14),941-944","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref=125","first-page":"1625","volume":"17","author":"Zhou T.","year":"2019","unstructured":"Zhou T.; Wang J.; Xin C.; Kong L.; Wang C.; Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer\u2019s disease: A clinical trial. Exp Ther Med 2019,17(3),1625-1630","journal-title":"Exp Ther Med"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11920-020-01147-2","volume":"22","author":"Glass O.M.","year":"2020","unstructured":"Glass O.M.; Hermida A.P.; Hershenberg R.; Schwartz A.C.; Considerations and current trends in the management of the geriatric patient on a consultation-liaison service. Curr Psychiatry Rep 2020,22(5),21","journal-title":"Curr Psychiatry Rep"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"e923232","DOI":"10.12659\/MSM.923232","volume":"26","author":"Xu L.","year":"2020","unstructured":"Xu L.; Yu H.; Sun H.; Hu B.; Geng Y.; Dietary melatonin therapy alleviates the lamina cribrosa damages in patients with mild cognitive impairments: A double-blinded, randomized controlled study. Med Sci Monit 2020,26,e923232","journal-title":"Med Sci Monit"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JAD-2008-13110","volume":"13","author":"Bakchine S.","year":"2008","unstructured":"Bakchine S.; Loft H.; Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease: Results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2008,13(1),97-107","journal-title":"J Alzheimers Dis"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1212\/01.wnl.0000266627.96040.5a","volume":"69","author":"Black S.E.","year":"2007","unstructured":"Black S.E.; Doody R.; Li H.; McRae T.; Jambor K.M.; Xu Y.; Sun Y.; Perdomo C.A.; Richardson S.; Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007,69(5),459-469","journal-title":"Neurology"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000086613","volume":"20","author":"Brodaty H.","year":"2005","unstructured":"Brodaty H.; Corey-Bloom J.; Potocnik F.C.; Truyen L.; Gold M.; Damaraju C.R.; Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 2005,20(2-3),120-132","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1474-4422(08)70261-8","volume":"8","author":"Burns A.","year":"2009","unstructured":"Burns A.; Bernabei R.; Bullock R.; Cruz Jentoft A.J.; Fr\u00f6lich L.; Hock C.; Raivio M.; Triau E.; Vandewoude M.; Wimo A.; Came E.; Van Baelen B.; Hammond G.L.; van Oene J.C.; Schwalen S.; Safety and efficacy of galantamine (Reminyl) in severe Alzheimer\u2019s disease (the SERAD study): A randomised, placebo-controlled, double-blind trial. Lancet Neurol 2009,8(1),39-47","journal-title":"Lancet Neurol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000017126","volume":"10","author":"Burns A.","year":"1999","unstructured":"Burns A.; Rossor M.; Hecker J.; Gauthier S.; Petit H.; M\u00f6ller H.J.; Rogers S.L.; Friedhoff L.T.; The effects of donepezil in Alzheimer\u2019s disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999,10(3),237-244","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2013.282834","volume":"311","author":"Dysken M.W.","year":"2014","unstructured":"Dysken M.W.; Sano M.; Asthana S.; Vertrees J.E.; Pallaki M.; Llorente M.; Love S.; Schellenberg G.D.; McCarten J.R.; Malphurs J.; Prieto S.; Chen P.; Loreck D.J.; Trapp G.; Bakshi R.S.; Mintzer J.E.; Heidebrink J.L.; Vidal-Cardona A.; Arroyo L.M.; Cruz A.R.; Zachariah S.; Kowall N.W.; Chopra M.P.; Craft S.; Thielke S.; Turvey C.L.; Woodman C.; Monnell K.A.; Gordon K.; Tomaska J.; Segal Y.; Peduzzi P.N.; Guarino P.D.; Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA 2014,311(1),33-44","journal-title":"JAMA"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/cns.12158","volume":"19","author":"Farlow M.R.","year":"2013","unstructured":"Farlow M.R.; Grossberg G.T.; Sadowsky C.H.; Meng X.; Somogyi M.; A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg\/24 h versus 4.6 mg\/24 h in severe Alzheimer\u2019s dementia. CNS Neurosci Ther 2013,19(10),745-752","journal-title":"CNS Neurosci Ther"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.clinthera.2010.06.019","volume":"32","author":"Farlow M.R.","year":"2010","unstructured":"Farlow M.R.; Salloway S.; Tariot P.N.; Yardley J.; Moline M.L.; Wang Q.; Brand-Schieber E.; Zou H.; Hsu T.; Satlin A.; Effectiveness and tolerability of high-dose (23 mg\/d) versus standard-dose (10 mg\/d) donepezil in moderate to severe Alzheimer\u2019s disease: A 24-week, randomized, double-blind study. Clin Ther 2010,32(7),1234-1251","journal-title":"Clin Ther"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1212\/WNL.57.4.613","volume":"57","author":"Feldman H.","year":"2001","unstructured":"Feldman H.; Gauthier S.; Hecker J.; Vellas B.; Subbiah P.; Whalen E.; Donepezil M.S.I.G.; A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer\u2019s disease. Neurology 2001,57(4),613-620","journal-title":"Neurology"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1046\/j.1468-1331.1999.640423.x","volume":"6","author":"Forette F.","year":"1999","unstructured":"Forette F.; Anand R.; Gharabawi G.; A phase II study in patients with Alzheimer\u2019s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol 1999,6(4),423-429","journal-title":"Eur J Neurol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"e35185","DOI":"10.1371\/journal.pone.0035185","volume":"7","author":"Fox C.","year":"2012","unstructured":"Fox C.; Crugel M.; Maidment I.; Auestad B.H.; Coulton S.; Treloar A.; Ballard C.; Boustani M.; Katona C.; Livingston G.; Efficacy of memantine for agitation in Alzheimer\u2019s dementia: A randomised double-blind placebo controlled trial. PLoS One 2012,7(5),e35185","journal-title":"PLoS One"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-013-0077-7","volume":"27","author":"Grossberg G.T.","year":"2013","unstructured":"Grossberg G.T.; Manes F.; Allegri R.F.; Guti\u00e9rrez-Robledo L.M.; Gloger S.; Xie L.; Jia X.D.; Pejovi\u0107 V.; Miller M.L.; Perhach J.L.; Graham S.M.; The safety, tolerability, and efficacy of once-daily memantine (28 mg): A multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer\u2019s disease taking cholinesterase inhibitors. CNS Drugs 2013,27(6),469-478","journal-title":"CNS Drugs"},{"key":"ref=140","first-page":"391","volume":"10","author":"Hager K.","year":"2014","unstructured":"Hager K.; Baseman A.S.; Nye J.S.; Brashear H.R.; Han J.; Sano M.; Davis B.; Richards H.M.; Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer\u2019s disease. Neuropsychiatr Dis Treat 2014,10,391-401","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1017\/S1041610213000239","volume":"25","author":"Herrmann N.","year":"2013","unstructured":"Herrmann N.; Gauthier S.; Boneva N.; Lemming O.M.; A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer\u2019s disease. Int Psychogeriatr 2013,25(6),919-927","journal-title":"Int Psychogeriatr"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3233\/JAD-151149","volume":"52","author":"Homma A.","year":"2016","unstructured":"Homma A.; Atarashi H.; Kubota N.; Nakai K.; Takase T.; Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in japanese patients with severe Alzheimer\u2019s disease: A randomized, double-blind trial. J Alzheimers Dis 2016,52(1),345-357","journal-title":"J Alzheimers Dis"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000122961","volume":"25","author":"Homma A.","year":"2008","unstructured":"Homma A.; Imai Y.; Tago H.; Asada T.; Shigeta M.; Iwamoto T.; Takita M.; Arimoto I.; Koma H.; Ohbayashi T.; Donepezil treatment of patients with severe Alzheimer\u2019s disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 2008,25(5),399-407","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000017259","volume":"11","author":"Homma A.","year":"2000","unstructured":"Homma A.; Takeda M.; Imai Y.; Udaka F.; Hasegawa K.; Kameyama M.; Nishimura T.; Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer\u2019s disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000,11(6),299-313","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa066583","volume":"357","author":"Howard R.J.","year":"2007","unstructured":"Howard R.J.; Juszczak E.; Ballard C.G.; Bentham P.; Brown R.G.; Bullock R.; Burns A.S.; Holmes C.; Jacoby R.; Johnson T.; Knapp M.; Lindesay J.; O\u2019Brien J.T.; Wilcock G.; Katona C.; Jones R.W.; DeCesare J.; Rodger M.; Donepezil for the treatment of agitation in Alzheimer\u2019s disease. N Engl J Med 2007,357(14),1382-1392","journal-title":"N Engl J Med"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.3233\/JAD-161117","volume":"56","author":"Jia J.","year":"2017","unstructured":"Jia J.; Wei C.; Jia L.; Tang Y.; Liang J.; Zhou A.; Li F.; Shi L.; Doody R.S.; Efficacy and safety of donepezil in Chinese patients with severe Alzheimer\u2019s disease: A randomized controlled trial. J Alzheimers Dis 2017,56(4),1495-1504","journal-title":"J Alzheimers Dis"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000080972","volume":"19","author":"Karaman Y.","year":"2005","unstructured":"Karaman Y.; Erdo\u011fan F.; K\u00f6seo\u011flu E.; Turan T.; Ersoy A.O.; A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 2005,19(1),51-56","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1176\/appi.ajp.160.11.2003","volume":"160","author":"Krishnan K.R.","year":"2003","unstructured":"Krishnan K.R.; Charles H.C.; Doraiswamy P.M.; Mintzer J.; Weisler R.; Yu X.; Perdomo C.; Ieni J.R.; Rogers S.; Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer\u2019s disease. Am J Psychiatry 2003,160(11),2003-2011","journal-title":"Am J Psychiatry"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00406-011-0234-2","volume":"262","author":"Likitjaroen Y.","year":"2012","unstructured":"Likitjaroen Y.; Meindl T.; Friese U.; Wagner M.; Buerger K.; Hampel H.; Teipel S.J.; Longitudinal changes of fractional anisotropy in Alzheimer\u2019s disease patients treated with galantamine: A 12-month randomized, placebo-controlled, double-blinded study. Eur Arch Psychiatry Clin Neurosci 2012,262(4),341-350","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/gps.2562","volume":"26","author":"Maher-Edwards G.","year":"2011","unstructured":"Maher-Edwards G.; Dixon R.; Hunter J.; Gold M.; Hopton G.; Jacobs G.; Hunter J.; Williams P.; SB-742457 and donepezil in Alzheimer disease: A randomized, placebo-controlled study. Int J Geriatr Psychiatry 2011,26(5),536-544","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000328929","volume":"1","author":"Nakamura Y.","year":"2011","unstructured":"Nakamura Y.; Imai Y.; Shigeta M.; Graf A.; Shirahase T.; Kim H.; Fujii A.; Mori J.; Homma A.; A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer\u2019s disease. Dement Geriatr Cogn Disord Extra 2011,1(1),163-179","journal-title":"Dement Geriatr Cogn Disord Extra"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/01.JGP.0000224350.82719.83","volume":"14","author":"Peskind E.R.","year":"2006","unstructured":"Peskind E.R.; Potkin S.G.; Pomara N.; Ott B.R.; Graham S.M.; Olin J.T.; McDonald S.; Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006,14(8),704-715","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/156720508783884576","volume":"5","author":"Porsteinsson A.P.","year":"2008","unstructured":"Porsteinsson A.P.; Grossberg G.T.; Mintzer J.; Olin J.T.; Memantine M.E.M.M.D.S.G.; Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008,5(1),83-89","journal-title":"Curr Alzheimer Res"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","volume":"54","author":"Raskind M.A.","year":"2000","unstructured":"Raskind M.A.; Peskind E.R.; Wessel T.; Yuan W.; Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000,54(12),2261-2268","journal-title":"Neurology"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"Reisberg B.","year":"2003","unstructured":"Reisberg B.; Doody R.; St\u00f6ffler A.; Schmitt F.; Ferris S.; M\u00f6bius H.J.; Memantine in moderate-to-severe Alzheimer\u2019s disease. N Engl J Med 2003,348(14),1333-1341","journal-title":"N Engl J Med"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1503\/cmaj.051432","volume":"174","author":"Rockwood K.","year":"2006","unstructured":"Rockwood K.; Fay S.; Song X.; MacKnight C.; Gorman M.; Attainment of treatment goals by people with Alzheimer\u2019s disease receiving galantamine: A randomized controlled trial. CMAJ 2006,174(8),1099-1105","journal-title":"CMAJ"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1212\/WNL.50.1.136","volume":"50","author":"Rogers S.L.","year":"1998","unstructured":"Rogers S.L.; Farlow M.R.; Doody R.S.; Mohs R.; Friedhoff L.T.; A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Neurology 1998,50(1),136-145","journal-title":"Neurology"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","volume":"318","author":"R\u00f6sler M.","year":"1999","unstructured":"R\u00f6sler M.; Anand R.; Cicin-Sain A.; Gauthier S.; Agid Y.; Dal-Bianco P.; St\u00e4helin H.B.; Hartman R.; Gharabawi M.; Bayer T.; Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: International randomised controlled trial. BMJ 1999,318(7184),633-638","journal-title":"BMJ"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","volume":"61","author":"Seltzer B.","year":"2004","unstructured":"Seltzer B.; Zolnouni P.; Nunez M.; Goldman R.; Kumar D.; Ieni J.; Richardson S.; Efficacy of donepezil in early-stage Alzheimer disease: A randomized placebo-controlled trial. Arch Neurol 2004,61(12),1852-1856","journal-title":"Arch Neurol"},{"key":"ref=160","first-page":"2944","volume":"8","author":"Shao Z.Q.","year":"2015","unstructured":"Shao Z.Q.; Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer\u2019s disease. Int J Clin Exp Med 2015,8(2),2944-2948","journal-title":"Int J Clin Exp Med"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/j.1532-5415.2001.49266.x","volume":"49","author":"Tariot P.N.","year":"2001","unstructured":"Tariot P.N.; Cummings J.L.; Katz I.R.; Mintzer J.; Perdomo C.A.; Schwam E.M.; Whalen E.; A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer\u2019s disease in the nursing home setting. J Am Geriatr Soc 2001,49(12),1590-1599","journal-title":"J Am Geriatr Soc"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"Tariot P.N.","year":"2004","unstructured":"Tariot P.N.; Farlow M.R.; Grossberg G.T.; Graham S.M.; McDonald S.; Gergel I.; Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004,291(3),317-324","journal-title":"JAMA"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","volume":"54","author":"Tariot P.N.","year":"2000","unstructured":"Tariot P.N.; Solomon P.R.; Morris J.C.; Kershaw P.; Lilienfeld S.; Ding C.; A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000,54(12),2269-2276","journal-title":"Neurology"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00019442-200303000-00007","volume":"11","author":"Tune L.","year":"2003","unstructured":"Tune L.; Tiseo P.J.; Ieni J.; Perdomo C.; Pratt R.D.; Votaw J.R.; Jewart R.D.; Hoffman J.M.; Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: Results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 2003,11(2),169-177","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/WAD.0b013e318065c495","volume":"21","author":"van Dyck C.H.","year":"2007","unstructured":"van Dyck C.H.; Tariot P.N.; Meyers B.; Malca Resnick E.; Memantine M.E.M.M.D.S.G.; A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007,21(2),136-143","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/arclin\/acy032","volume":"34","author":"Vila-Castelar C.","year":"2019","unstructured":"Vila-Castelar C.; Ly J.J.; Kaplan L.; Van Dyk K.; Berger J.T.; Macina L.O.; Stewart J.L.; Foldi N.S.; Attention measures of accuracy, variability, and fatigue detect early response to donepezil in Alzheimer\u2019s disease: A randomized, double-blind, placebo-controlled pilot trial. Arch Clin Neuropsychol 2019,34(3),277-289","journal-title":"Arch Clin Neuropsychol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/JCP.0b013e31829a876a","volume":"33","author":"Wang T.","year":"2013","unstructured":"Wang T.; Huang Q.; Reiman E.M.; Chen K.; Li X.; Li G.; Lin Z.; Li C.; Xiao S.; Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial. J Clin Psychopharmacol 2013,33(5),636-642","journal-title":"J Clin Psychopharmacol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","volume":"321","author":"Wilcock G.K.","year":"2000","unstructured":"Wilcock G.K.; Lilienfeld S.; Gaens E.; Efficacy and safety of galantamine in patients with mild to moderate Alzheimer\u2019s disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000,321(7274),1445-1449","journal-title":"BMJ"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/gps.409","volume":"16","author":"Wilkinson D.","year":"2001","unstructured":"Wilkinson D.; Murray J.; Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer\u2019s disease. Int J Geriatr Psychiatry 2001,16(9),852-857","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/gps.1788","volume":"22","author":"Winblad B.","year":"2007","unstructured":"Winblad B.; Cummings J.; Andreasen N.; Grossberg G.; Onofrj M.; Sadowsky C.; Zechner S.; Nagel J.; Lane R.; A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer\u2019s disease--rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007,22(5),456-467","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","volume":"367","author":"Winblad B.","year":"2006","unstructured":"Winblad B.; Kilander L.; Eriksson S.; Minthon L.; B\u00e5tsman S.; Wetterholm A.L.; Jansson-Blixt C.; Haglund A.; Donepezil in patients with severe Alzheimer\u2019s disease: Double-blind, parallel-group, placebo-controlled study. Lancet 2006,367(9516),1057-1065","journal-title":"Lancet"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000430808","volume":"40","author":"Zhang N.","year":"2015","unstructured":"Zhang N.; Wei C.; Du H.; Shi F.D.; Cheng Y.; The effect of memantine on cognitive function and behavioral and psychological symptoms in mild-to-moderate Alzheimer\u2019s disease patients. Dement Geriatr Cogn Disord 2015,40(1-2),85-93","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/cns.12521","volume":"22","author":"Zhang Z.X.","year":"2016","unstructured":"Zhang Z.X.; Hong Z.; Wang Y.P.; He L.; Wang N.; Zhao Z.X.; Zhao G.; Shang L.; Weisskopf M.; Callegari F.; Strohmaier C.; Rivastigmine patch in Chinese patients with probable Alzheimer\u2019s disease: A 24-week, randomized, double-blind parallel-group study comparing rivastigmine patch (9.5 mg\/24 h) with capsule (6 mg twice daily). CNS Neurosci Ther 2016,22(6),488-496","journal-title":"CNS Neurosci Ther"},{"key":"ref=174","first-page":"52","volume":"21","author":"Hughes R.J.","year":"1998","unstructured":"Hughes R.J.; Sack R.L.; Lewy A.J.; The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: Assessment in a clinical trial of melatonin replacement. Sleep 1998,21(1),52-68","journal-title":"Sleep"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s41999-018-0068-9","volume":"9","author":"Morales-Delgado R.","year":"2018","unstructured":"Morales-Delgado R.; C\u00e1mara-Lemarroy C.R.; Salinas-Mart\u00ednez R.; G\u00e1mez-Trevi\u00f1o D.; Arredondo-Jaime A.; Hern\u00e1ndez-Maldonado E.; Guajardo-\u00c1lvarez G.; A randomized placebo-controlled trial evaluating the effect of melatonin on sleep quality in patients with mild-moderate dementia. Eur Geriatr Med 2018,9(4),449-454","journal-title":"Eur Geriatr Med"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0079-6123(08)60216-2","volume":"72","author":"Swaab D.F.","year":"1987","unstructured":"Swaab D.F.; Roozendaal B.; Ravid R.; Velis D.N.; Gooren L.; Williams R.S.; Suprachiasmatic nucleus in aging, Alzheimer\u2019s disease, transsexuality and Prader-Willi syndrome. Prog Brain Res 1987,72,301-310","journal-title":"Prog Brain Res"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0006-8993(85)91350-2","volume":"342","author":"Swaab D.F.","year":"1985","unstructured":"Swaab D.F.; Fliers E.; Partiman T.S.; The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res 1985,342(1),37-44","journal-title":"Brain Res"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1176\/appi.ajp.158.5.704","volume":"158","author":"Volicer L.","year":"2001","unstructured":"Volicer L.; Harper D.G.; Manning B.C.; Goldstein R.; Satlin A.; Sundowning and circadian rhythms in Alzheimer\u2019s disease. Am J Psychiatry 2001,158(5),704-711","journal-title":"Am J Psychiatry"},{"key":"ref=179","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/sleep\/20.1.24","volume":"20","author":"Ancoli-Israel S.","year":"1997","unstructured":"Ancoli-Israel S.; Klauber M.R.; Jones D.W.; Kripke D.F.; Martin J.; Mason W.; Pat-Horenczyk R.; Fell R.; Variations in circadian rhythms of activity, sleep, and light exposure related to dementia in nursing-home patients. Sleep 1997,20(1),18-23","journal-title":"Sleep"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2869.2005.00462.x","volume":"14","author":"Bonanni E.","year":"2005","unstructured":"Bonanni E.; Maestri M.; Tognoni G.; Fabbrini M.; Nucciarone B.; Manca M.L.; Gori S.; Iudice A.; Murri L.; Daytime sleepiness in mild and moderate Alzheimer\u2019s disease and its relationship with cognitive impairment. J Sleep Res 2005,14(3),311-317","journal-title":"J Sleep Res"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrneurol.2013.269","volume":"10","author":"Ju Y.E.","year":"2014","unstructured":"Ju Y.E.; Lucey B.P.; Holtzman D.M.; Sleep and Alzheimer disease pathology--a bidirectional relationship. Nat Rev Neurol 2014,10(2),115-119","journal-title":"Nat Rev Neurol"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1001\/jamaneurol.2013.4215","volume":"70","author":"Lim A.S.","year":"2013","unstructured":"Lim A.S.; Yu L.; Kowgier M.; Schneider J.A.; Buchman A.S.; Bennett D.A.; Modification of the relationship of the apolipoprotein E \u03b54 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol 2013,70(12),1544-1551","journal-title":"JAMA Neurol"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/jamaneurol.2013.2334","volume":"70","author":"Ju Y.E.","year":"2013","unstructured":"Ju Y.E.; McLeland J.S.; Toedebusch C.D.; Xiong C.; Fagan A.M.; Duntley S.P.; Morris J.C.; Holtzman D.M.; Sleep quality and preclinical Alzheimer disease. JAMA Neurol 2013,70(5),587-593","journal-title":"JAMA Neurol"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/jamaneurol.2013.4258","volume":"70","author":"Spira A.P.","year":"2013","unstructured":"Spira A.P.; Gamaldo A.A.; An Y.; Wu M.N.; Simonsick E.M.; Bilgel M.; Zhou Y.; Wong D.F.; Ferrucci L.; Resnick S.M.; Self-reported sleep and \u03b2-amyloid deposition in community-dwelling older adults. JAMA Neurol 2013,70(12),1537-1543","journal-title":"JAMA Neurol"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.1241224","volume":"342","author":"Xie L.","year":"2013","unstructured":"Xie L.; Kang H.; Xu Q.; Chen M.J.; Liao Y.; Thiyagarajan M.; O\u2019Donnell J.; Christensen D.J.; Nicholson C.; Iliff J.J.; Takano T.; Deane R.; Nedergaard M.; Sleep drives metabolite clearance from the adult brain. Science 2013,342(6156),373-377","journal-title":"Science"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/0748730406293854","volume":"21","author":"Kalsbeek A.","year":"2006","unstructured":"Kalsbeek A.; Palm I.F.; La Fleur S.E.; Scheer F.A.; Perreau-Lenz S.; Ruiter M.; Kreier F.; Cailotto C.; Buijs R.M.; SCN outputs and the hypothalamic balance of life. J Biol Rhythms 2006,21(6),458-469","journal-title":"J Biol Rhythms"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/jpi.12360","volume":"61","author":"Reiter R.J.","year":"2016","unstructured":"Reiter R.J.; Mayo J.C.; Tan D.X.; Sainz R.M.; Alatorre-Jimenez M.; Qin L.; Melatonin as an antioxidant: Under promises but over delivers. J Pineal Res 2016,61(3),253-278","journal-title":"J Pineal Res"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3233\/JAD-161088","volume":"57","author":"T\u00f6nnies E.","year":"2017","unstructured":"T\u00f6nnies E.; Trushina E.; Oxidative stress, synaptic dysfunction, and\u00a0Alzheimer\u2019s disease. J Alzheimers Dis 2017,57(4),1105-1121","journal-title":"J Alzheimers Dis"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1745-7254.2006.00260.x","volume":"27","author":"Wang J.Z.","year":"2006","unstructured":"Wang J.Z.; Wang Z.F.; Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin 2006,27(1),41-49","journal-title":"Acta Pharmacol Sin"},{"key":"ref=190","first-page":"83","volume":"20","author":"Zhu L.Q.","year":"2005","unstructured":"Zhu L.Q.; Wang S.H.; Ling Z.Q.; Wang Q.; Hu M.Q.; Wang J.Z.; Inhibition of melatonin biosynthesis activates protein kinase a and induces Alzheimer-like tau hyperphosphorylation in rats. Chin Med Sci J 2005,20(2),83-87","journal-title":"Chin Med Sci J"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X20666220420122322","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/203848\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X20666220420122322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T16:38:37Z","timestamp":1666888717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/203848\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":190,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x20666220420122322","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}